Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54,906 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Terminated Phase 4 Interventional Results available

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

NCT00449007
View directory record Official record
Conditions
Depression, Alcoholism, Suicidal Behavior
Interventions
fluoxetine, bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 30, 2026, 9:27 AM EDT
Completed No phase listed Observational

Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT

NCT02081092
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

NCT00791336
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nelfinavir
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

NCT03396211
View directory record Official record
Conditions
Cancer
Interventions
Apatinib, Nivolumab
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed No phase listed Observational

G-Tech Feasibility Study for Early Detection of a Post-op Ileus

NCT02673671
View directory record Official record
Conditions
Post-operative Ileus
Interventions
G-Tech Myoelectric recording device
Device
Lead sponsor
G-Tech Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

NCT00053209
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
121
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

NCT02364609
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Pembrolizumab
Drug · Biological
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™

NCT02221232
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, ZuraPrep, ZuraPrep Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

NCT02556632
View directory record Official record
Conditions
Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions
Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 9:27 AM EDT
Terminated Phase 3 Interventional Results available

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplant, Rituximab
Radiation · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia

NCT00455663
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

NCT00003298
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
30
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Completed No phase listed Observational

Compliance With Once Daily Glaucoma Medication

NCT00333463
View directory record Official record
Conditions
Compliance
Interventions
Intervention
Behavioral
Lead sponsor
Alcon Research
Industry
Eligibility
Not listed
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Immune Dysregulation in Hepatitis C Patients With or Without Arthritis

NCT01195987
View directory record Official record
Conditions
Hepatitis C Patients
Interventions
Not listed
Lead sponsor
The Center for Rheumatic Disease, Allergy, & Immunology
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib in Treating Patients With Metastatic Kidney Cancer

NCT00276614
View directory record Official record
Conditions
Kidney Cancer
Interventions
bortezomib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

NCT03240016
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Abraxane
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 30, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT00043121
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

NCT04520321
View directory record Official record
Conditions
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
Interventions
TTHX1114(NM141), Vehicle (placebo)
Drug · Other
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Petaluma, California • Jacksonville, Florida • Hoffman Estates, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT01118221
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
pulmonary rehabilitation
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

N-of-1 Trials Using mHealth in Chronic Pain

NCT02116621
View directory record Official record
Conditions
Musculoskeletal Pain, Chronic Pain
Interventions
Trialist Intervention, smartphone
Behavioral · Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 75 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Mather, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 30, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

NCT00004014
View directory record Official record
Conditions
Prostate Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 30, 2026, 9:27 AM EDT